Discovery of Macrocycle-Based HPK1 Inhibitors for T-Cell-Based Immunotherapy.
暂无分享,去创建一个
Wei Huang | Guang-Fu Yang | Mingfang Wang | Zhi-Zheng Wang | Yi Gong | Qian-Hui Cheng | Zixi Li | Cheng-Xiang Duan
[1] Kuojun Zhang,et al. The development of small-molecule inhibitors targeting HPK1. , 2022, European journal of medicinal chemistry.
[2] Wei Huang,et al. Discovery of 3-pyrazolyl-substituted pyrazolo[1,5-a]pyrimidine derivatives as potent TRK inhibitors to overcome clinically acquired resistance. , 2022, European journal of medicinal chemistry.
[3] Q. You,et al. Hematopoietic Progenitor Kinase 1 in Tumor Immunology: A Medicinal Chemistry Perspective. , 2022, Journal of medicinal chemistry.
[4] Wei Huang,et al. Conformational adjustment overcomes multiple drug-resistance mutants of tropomyosin receptor kinase. , 2022, European journal of medicinal chemistry.
[5] Hoai An Le Thi,et al. Discovery of Spiro-azaindoline Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1). , 2021, ACS medicinal chemistry letters.
[6] Wei Huang,et al. Discovery of Next-Generation Tropomyosin Receptor Kinase Inhibitors for Combating Multiple Resistance Associated with Protein Mutation. , 2021, Journal of medicinal chemistry.
[7] Zhijun Sun,et al. Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges , 2021, Cancer communications.
[8] Ming Jiang,et al. Developing a Novel Anticancer Gold(III) Agent to Integrate Chemotherapy and Immunotherapy. , 2021, Journal of medicinal chemistry.
[9] I. Linney,et al. Inhibitors of immuno-oncology target HPK1 – a patent review (2016 to 2020) , 2021, Expert opinion on therapeutic patents.
[10] X. Fradera,et al. Identification of Potent Reverse Indazole Inhibitors for HPK1. , 2021, ACS medicinal chemistry letters.
[11] Alan S. Futran,et al. Discovery of Orally Active Isofuranones as Potent, Selective Inhibitors of Hematopoetic Progenitor Kinase 1 , 2021, ACS medicinal chemistry letters.
[12] E. Ileana-Dumbrava. Unraveling the mysteries of microsatellite instability , 2021, Science Translational Medicine.
[13] Haiyan Xu,et al. Pharmacological inhibition of hematopoietic progenitor kinase 1 positively regulates T-cell function , 2020, PloS one.
[14] Yonghui Wang,et al. Adenosine A2A Receptor Antagonists for Cancer Immunotherapy. , 2020, Journal of medicinal chemistry.
[15] D. Spring,et al. Strategies for the Diversity-Oriented Synthesis of Macrocycles. , 2019, Chemical reviews.
[16] Vinay Prasad,et al. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs , 2019, JAMA network open.
[17] M. Cummings,et al. Structure-Based Macrocycle Design in Small-Molecule Drug Discovery and Simple Metrics To Identify Opportunities for Macrocyclization of Small-Molecule Ligands. , 2019, Journal of medicinal chemistry.
[18] G. Dranoff,et al. Cancer Immunotherapy: Beyond Checkpoint Blockade , 2019, Annual Review of Cancer Biology.
[19] BinQing Wei,et al. Hematopoietic Progenitor Kinase-1 Structure in a Domain-Swapped Dimer. , 2019, Structure.
[20] I. Mellman,et al. The Kinase Activity of Hematopoietic Progenitor Kinase 1 Is Essential for the Regulation of T Cell Function. , 2018, Cell reports.
[21] T. Tan,et al. GLK-IKKβ signaling induces dimerization and translocation of the AhR-RORγt complex in IL-17A induction and autoimmune disease , 2018, Science Advances.
[22] M. Ahluwalia,et al. Management of Brain Metastases in the New Era of Checkpoint Inhibition , 2018, Current Neurology and Neuroscience Reports.
[23] Jedd D. Wolchok,et al. Cancer immunotherapy using checkpoint blockade , 2018, Science.
[24] Pornpimol Charoentong,et al. Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution , 2018, Nature Communications.
[25] C. Lukacs,et al. Germinal‐center kinase‐like kinase co‐crystal structure reveals a swapped activation loop and C‐terminal extension , 2017, Protein science : a publication of the Protein Society.
[26] Wei Liu,et al. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain expos , 2014, Journal of medicinal chemistry.
[27] T. Tan,et al. The kinase GLK controls autoimmunity and NF-κB signaling by activating the kinase PKC-θ in T cells , 2011, Nature Immunology.
[28] É. Marsault,et al. Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery. , 2011, Journal of medicinal chemistry.
[29] H. Yee,et al. Hematopoietic progenitor kinase 1 is a critical component of prostaglandin E2-mediated suppression of the anti-tumor immune response , 2009, Cancer Immunology, Immunotherapy.
[30] S. Alzabin,et al. Hematopoietic Progenitor Kinase 1 Is a Negative Regulator of Dendritic Cell Activation , 2009, The Journal of Immunology.
[31] Stephen P. Hale,et al. The exploration of macrocycles for drug discovery — an underexploited structural class , 2008, Nature Reviews Drug Discovery.
[32] S. Sawasdikosol,et al. Hematopoietic progenitor kinase 1 (HPK1) negatively regulates prostaglandin E2-induced fos gene transcription. , 2003, Blood.
[33] OUP accepted manuscript , 2022, Briefings In Bioinformatics.
[34] T. Tan,et al. Hematopoietic progenitor kinase 1 negatively regulates T cell receptor signaling and T cell–mediated immune responses , 2007, Nature Immunology.